Zydus Lifesciences Limited — Updates, 07-01-2025: Press Release

Zydus Lifesciences Ltd. has entered a strategic agreement with CVS Caremark to include its products Zituvio, Zituvimet, and Zituvimet XR in CVS Caremark's template formulary effective January 1, 2025. These products, which contain sitagliptin and combinations with metformin hydrochloride, specifically target improved glycemic control in adults with type 2 diabetes. This partnership strengthens Zydus’ position in the U.S. market, tapping into a growing segment within the $10 billion DPP-IV inhibitors market. The CEO of Zydus Pharmaceuticals USA emphasized that this collaboration affirms their commitment to enhancing patient access to quality medications at reduced costs. This agreement presents an opportunity for Zydus to enhance its market presence and should be watched closely by investors for potential growth in revenue and market share.